Article Text

Download PDFPDF
Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome
  1. A Sarkozy1,2,
  2. E Conti1,
  3. M Cristina Digilio3,
  4. B Marino4,
  5. E Morini1,2,
  6. G Pacileo5,
  7. M Wilson6,
  8. R Calabrò5,
  9. A Pizzuti1,2,
  10. B Dallapiccola1,2
  1. 1CSS Hospital, IRCCS, San Giovanni Rotondo, Italy, and CSS-Mendel Institute, Rome, Italy
  2. 2Department of Experimental Medicine and Pathology, University “La Sapienza”, Rome, Italy
  3. 3Division of Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome, Italy
  4. 4Section of Pediatric Cardiology, Institute of Pediatrics, University “La Sapienza”, Rome, Italy
  5. 5Pediatric Cardiology, Monaldi Hospital, Naples, Italy
  6. 6Department of Clinical Genetics, The Children’s Hospital, Sydney, Australia
  1. Correspondence to:
 Dr Pizzuti
 Istituto CSS-Mendel, Viale Regina Margherita 261, 00198 Rome, Italy; a.pizzuticss-mendel.it

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Multiple lentigines LEOPARD syndrome (MIM 151100) is an autosomal dominant multiple congenital anomaly syndrome, with high penetrance and markedly variable expression.1 The acronym LEOPARD was coined by Gorlin et al. in 1971 as a mnemonic of the major features of this disorder: multiple lentigines, ECG conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness.2 It is also known as cardiocutaneous syndrome, Moynahan syndrome, lentiginosis profuse, and progressive cardiomyopathic lentiginosis.3,4 Voron et al. proposed some diagnostic criteria for multiple lentigines LEOPARD syndrome.5 More than 100 cases have been described, and one review has been published.5,6

Multiple lentigines LEOPARD syndrome shares many features with Noonan syndrome (MIM 163950),7–9 in which lentigines and deafness usually are not present. About 40% of patients with Noonan syndrome have missense mutations in the PTPN11 gene, which encodes for the protein tyrosine phosphatase SHP2.10–14 Multiple lentigines LEOPARD syndrome has proved to be allelic to Noonan syndrome,15,16 with two recurrent PTPN11 mutations in exons 7 (Tyr279Cys) and 12 (Thr468Met). Recently, we reported a novel PTPN11 mutation (Gln506Pro) in a unique patient with multiple lentigines LEOPARD syndrome, which suggests that mutations other than Tyr279Cys and Thr468Met could be found in these patients.17 As PTPN11 mutations in multiple lentigines LEOPARD syndrome and Noonan syndrome are exclusive to these conditions, the distinctive manifestations of these disorders likely result from different molecular mechanisms. For instance, as commented in a recent report, the cardiac phenotypes in patients with Noonan syndrome and those with multiple lentigines LEOPARD syndrome with PTPN11 mutations are rather dissimilar, with pulmonary valve stenosis prevailing in the former and hypertrophic cardiomyopathy in the latter.18

We examined the PTPN11 gene in a consecutive series …

View Full Text

Footnotes

  • Funding: This study was supported in part by grants from the Italian Ministry of Health (RC 2002 and 2003) and from the Italian Ministry of Instruction, University and Research (Grant 40% to BD).

  • Conflicts of interest: none declared.